Bugging inflammation in lung cancer

How the lung microbiome highlights therapeutic avenues for lung cancer

An MIT study linking the lung microbiome to inflammation offers new therapeutic strategies for treating lung cancer and a mechanistic rationale for testing cytokine inhibitors in the disease, a tack Novartis AG (NYSE:NVS; SIX:NOVN) has already taken.

In a Cell paper last month, a team from the

Read the full 465 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE